Log in

Relevant bibliographies by topics / Carcinoma Prostata / Books

Books on the topic 'Carcinoma Prostata'

To see the other types of publications on this topic, follow the link: Carcinoma Prostata.

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 42 books for your research on the topic 'Carcinoma Prostata.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Wernert, Nicholas. Immunhistochemie der Prostata und des Prostatakarzinoms: Neue Aspekte der Histogenese = Immunohistochemistry of the prostate and prostate carcinoma : new aspects of histogenesis. Stuttgart: Fischer, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

M, Bolla, Rambeaud J. J, and Vincent François, eds. Local prostatic carcinoma. Basel: Karger, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

V, D'Amico Anthony, and Hanks Gerald E, eds. Advances in the radiotherapeutic management of carcinoma of the prostate. New York: Chapman & Hall, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hayat, M. A. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas: Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma. Burlington: Elsevier, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Petrovich, Zbigniew, Luc Baert, and Luther W. Brady, eds. Carcinoma of the Prostate. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-60956-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

E, Altwein Jens, Faul Peter, and Schneider W. 1937-, eds. Incidental carcinoma of the prostate. Berlin: Springer-Verlag, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Altwein, Jens E., Peter Faul, and Wolfgang Schneider, eds. Incidental Carcinoma of the Prostate. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76129-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gerhard, Aumüller, and Helpap Burkhard, eds. The prostate: Benign prostatic hyperplasia and carcinoma : actual positions and future perspectives. Stuttgart: Georg Thieme Verlag, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hayat, M. A., ed. General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-8442-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

service), SpringerLink (Online, ed. General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Dordrecht: Springer Netherlands, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Rösch, Katharina. Mutationssuche im Prostate Carcinoma Tumor Antigen 1 (PCTA-1) Gen, einem Kandidatengen für das hereditäre prostatakarzinom beim Mensch, lokalisiert auf dem PcaP Locus in 1q42.3-43. [S.l.]: [s.n.], 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Frohmüller, H. G. W. 1928- and Wirth Manfred P, eds. Uro-oncology: Current status and future trends : proceedings of a Uro-Oncological Workshop, held in Würzburg, Federal Republic of Germany, June 22-25, 1988. New York: Wiley-Liss, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hafez, E. S. E. Prostatic Carcinoma. Ingramcontent, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Carton, James. Urological pathology. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199591633.003.0010.

Full text

Abstract:

Genitourinary malformations 158Urinary tract infection 160Urinary tract obstruction 162Urinary calculi 164Cystic renal diseases 165Benign renal tumours 166Renal cell carcinoma 168Childhood renal tumours 170Urothelial carcinomas 172Benign prostatic hyperplasia 174Prostate carcinoma 176Testicular germ cell tumours 178...

APA, Harvard, Vancouver, ISO, and other styles

15

Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma. Elsevier, 2002. http://dx.doi.org/10.1016/s1874-5784(02)x8001-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

(Editor), Anthony V. D'Amico, and Gerald E. Hanks (Editor), eds. Advances in the Radiotherapeutic Management of Carcinoma of the Prostate. Oxford Univ Pr (Txt), 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Carton, James. Urological pathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0011.

Full text

Abstract:

This chapter discusses urological pathology and covers diseases of the urinary tract managed by urologists. This includes genitourinary malformations, urinary tract infection, urinary tract obstruction, urinary calculi, cystic renal diseases, benign renal tumours, renal cell carcinoma (RCC), childhood renal tumours, urothelial carcinoma, benign prostatic hyperplasia (BPH), prostate carcinoma, testicular germ cell tumours, testicular non-germ cell tumours, paratesticular diseases, urethral diseases, penile diseases, and scrotal diseases.

APA, Harvard, Vancouver, ISO, and other styles

18

Schneider, Wolfgang, Peter Faul, and Jens E. Altwein. Incidental Carcinoma of the Prostate. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bolla, M., J. J. Rambeaud, and F. Vincent, eds. Local Prostatic Carcinoma. S. Karger AG, 1995. http://dx.doi.org/10.1159/isbn.978-3-318-03430-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Hayat, M. A. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, Volume 2: Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma. Academic Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hayat, M. A. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, Volume 2: Molecular Pathology, Colorectal Carcinoma, and Prostate Carcinoma. Academic Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Incidental Carcinoma of the Prostate. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Schneider, Wolfgang, Peter Faul, and Jens E. Altwein. Incidental Carcinoma of the Prostate. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

(Editor), Zbigniew Petrovich, Luc Baert (Editor), and Luther W. Brady (Editor), eds. Carcinoma of the Prostate: Innovations in Management. Springer-Verlag Telos, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Skinner, D. G., L. W. Brady, Luther W. Brady, Luc Baert, and Zbigniew Petrovich. Carcinoma of the Prostate: Innovations in Management. Springer London, Limited, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Skinner, D. G., L. W. Brady, Luc Baert, Zbigniew Petrovich, and H. P. Heilmann. Carcinoma of the Prostate: Innovations in Management. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Helpap. The Prostrate: Benign Prostatic Hyperplasia and Carcinoma: Actual Positions and Future Perspectives. Thieme Publishing Group, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Prostatic Carcinoma: Biology and Diagnosis. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hafez, E. S., and E. Spring-Mills. Prostatic Carcinoma: Biology and Diagnosis. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zbigniew, Petrovich, Baert L. (Luc), and Brady Luther W. 1925-, eds. Carcinoma of the prostate: Innovations in management. Berlin: Springer, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

31

(Editor), Zbigniew Petrovich, Luc Baert (Editor), and Luther W. Brady (Editor), eds. Carcinoma of the Prostate: Innovations in Management (Medical Radiology). Springer-Verlag, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hayat, M. A. Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Springer Netherlands, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Debruyne, F. M. Future Prospects in the Management of Prostatic Carcinoma (European Urology). S. Karger AG (Switzerland), 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Huland, H. Latent Prostatic Carcinoma: Epidemiology-Biology-Clinical Significance-Detection and Prevention (Eurpean Urology, 4). S Karger Pub, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

35

Thun, Michael J., and Neal D. Freedman. Tobacco. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0011.

Full text

Abstract:

Tobacco is the leading preventable cause of cancer and other non-communicable diseases worldwide. IARC and the U.S. Surgeon General designate over twenty cancer sites or subsites as causally related to active cigarette smoking, including lung, oral cavity, nasal cavity and accessory sinuses, naso- oro- and hypopharynx, larynx, esophagus (squamous cell carcinoma and adenocarcinoma), stomach, pancreas, colorectum, liver, kidney (adeno- and transitional cell carcinoma), ureter, urinary bladder, uterine cervix, ovary (mucinous), and acute myeloid leukemia. Even this list may be incomplete, as it does not include sites for which the evidence is still considered limited, such as advanced prostate cancer and breast cancer. In addition to cigarettes, all other forms of smoked and conventional smokeless tobacco products, as well as involuntary exposure to tobacco smoke, cause cancer. The use of multiple tobacco products continues to complicate tobacco control, as does the recent introduction of novel products such as e-cigarettes.

APA, Harvard, Vancouver, ISO, and other styles

36

Transperineal interstitial microwave therapy for recurrent localized carcinoma of the prostate following brachytherapy seed implantation: Phantom studies. Ottawa: National Library of Canada, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Lee, Olivia T., Jennifer N. Wu, Frederick J. Meyers, and Christopher P. Evans. Genitourinary aspects of palliative care. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0084.

Full text

Abstract:

Genitourinary tract diseases in the palliative care setting most commonly involve urinary tract obstruction, intractable bleeding, fistulae, and bladder-associated pain. Sources of obstruction in the lower urinary tract include benign prostatic hyperplasia, invasive prostate or bladder cancer, urethral stricture, or bladder neck contracture. Upper tract obstruction includes intraluminal or extraluminal blockage of the renal collecting system and ureters, such as transitional cell carcinoma, fibroepithelial polyps, stricture, stones, pelvic or retroperitoneal malignancy, fibrosis, or prior radiation. Untreated, obstructive uropathy leads to elevated bladder, ureter, and kidney pressures, bladder dysfunction, urolithiasis, renal failure, pyelonephritis, or urosepsis. Intractable haematuria can cause problematic anaemia, frequent transfusions, clot retention, haemorrhagic shock, and death. In addition, urinary tract fistulae such as vesicovaginal and vesicoenteric fistulae are common in patients who have had prior pelvic surgery or radiation especially in the setting of immunocompromise, poor nutrition, and infection. Untreated, these symptoms lead to rash, skin breakdown, ulcers, chronic infection, and sepsis. Lastly, pelvic and bladder pain, depending on aetiology can be treated with oral medications, intravesical therapies, or surgical therapies such as palliative resection or urinary diversion. Selection of tests and treatment modalities in the palliative care setting should be based on using the least invasive means to achieve the most relief in suffering. Some genitourinary conditions are potentially fatal, and in the acute or subacute setting, require re-evaluation of the end-of-life goals and wishes of the patient and family.

APA, Harvard, Vancouver, ISO, and other styles

38

Brosig, W., and G. Raspé. International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, November 13 To 15 1969: Life Science Monographs. Elsevier Science & Technology Books, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

(Editor), Lea I. Sekely, ed. In Vitro Models for Cancer Research: Carcinomas of the Prostate and Testis (In Vitro Models for Cancer Research). Reader's Digest Young Families, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Das, Raj, Susan Heenan, and Uday Patel. Magnetic resonance imaging in urology. Edited by Michael Weston. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0134.

Full text

Abstract:

Magnetic resonance imaging is essential for urological imaging. It offers excellent soft tissue contrast and resolution, allowing manipulation of tissue contrast with different image weighting and sequences. The multiplanar aspect of MRI allows image acquisition in different planes and degrees of obliquity to best exhibit pathology. The basic physics of MRI is explored initially with explanation of image weighting, sequences, and diffusion-weighted imaging. The chapter is then divided into renal, bladder, and prostate MRI imaging. The paragraphs on renal MRI outline renal mass analysis and include characterization and assessment of cystic and fat-containing lesions. Staging of renal carcinoma with MRI is also discussed, along with its advantages compared with CT staging. Throughout the text, the key diagnostic MRI features with each disease and organ, and the pitfalls and caveats of MRI imaging are emphasized.

APA, Harvard, Vancouver, ISO, and other styles

41

Cutter, David, and Martin Scott-Brown. Treatment of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0325.

Full text

Abstract:

The variety of conditions that are considered to be ‘cancer’ is extremely wide, with marked variation in the management approach from disease to disease. A common feature in the management of malignant conditions, however, is the involvement of a wide range of medical professionals at different stages of the patient pathway. This commonly includes physicians, surgeons, radiologists, pathologists, medical oncologists, radiation oncologists, and specialist nurses, as well as a plethora of other allied disciplines. As such, a practice that has been widely adopted is to work as a multidisciplinary team (MDT), with regular meetings to decide the appropriate treatment for each patient with a cancer diagnosis, on an individual and case-by-case basis. The main treatment modalities for the treatment of cancer are surgery, radiotherapy, and chemotherapy. While these are often combined to form a multimodality therapy, they are all, in isolation, potentially radical (curative) therapies for certain conditions. For example, surgery (in the case of a Stage I colon adenocarcinoma), radiotherapy (in the case of early laryngeal squamous cell carcinoma), and chemotherapy (in the case of acute lymphoblastic leukaemia) are all curative as single-modality treatments. It is commonly the case, however, for a patient to require more than one mode of therapy to achieve the best outcome, for example a combination of surgery, chemotherapy, and radiotherapy for early breast cancer. It can also be the case that two or more different management strategies are thought to give equivalent oncological results, for example surgery or radiotherapy for early prostate cancer. In this situation, the MDT and the patient need to decide on the ‘best’ management plan for the individual, based on their personal and professional opinions and on the differing toxicity profiles of the alternate treatments.

APA, Harvard, Vancouver, ISO, and other styles

42

Grant, Warren, and Martin Scott-Brown. Prevention of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0350.

Full text

Abstract:

In the UK, the four commonest cancers—lung cancer, breast cancer, colon cancer, and prostate cancer—result in around 62 000 deaths every year. Although deaths from cancer have fallen in the UK over the last 20 years, the UK still suffers from higher cancer death rates than many other countries in Western Europe. In 1999, the UK government produced a White Paper called Saving Lives: Our Healthier Nation that outlined a national target to reduce the death rate from cancer by at least 20% in people under 75 by 2010. The subsequent NHS Cancer Plan of 2000 designed a framework by which to achieve this target through effective prevention, screening, and treatment programmes as well as restructuring and developing new diagnostic and treatment facilities. But do we know enough about the biology of the development of cancer for government health policies alone to force dramatic changes in survival? The science behind the causes of cancer tells us that its origin lies in acquired or inherited genetic abnormalities. Inherited gene mutation syndromes and exposure to environmental mutagens cause cancer, largely through abnormalities in DNA repair mechanisms, leading to uncontrolled cell proliferation. Although screening those thought to be at highest risk, and regulating exposure to environmental carcinogens such as tobacco or ionizing radiation, have reduced, and will continue to reduce, cancer deaths, there are many other environmental factors that have been shown to increase the population risk of cancer. These will be outlined in this chapter. However, the available evidence is largely from retrospective and cross-sectional population-based studies and therefore limits the ability to apply this knowledge to the risk of the individual patient who may been seen in clinic. Although we may be able to put him or her into a high-, intermediate-, or low-risk category, the question ‘will I get cancer, doc?’ is one that we cannot answer with certainty. The NHS Cancer Plan of 2000, designed to reduce cancer deaths in this country and to bring UK treatment results in line with those other countries in Europe, focuses on preventing malignancy as part of its comprehensive cancer management strategy. It highlights that the rich are less likely to develop cancer, and will survive longer if they are diagnosed than those who live in poverty. This may reflect available treatment options, but is more likely to be related to the lifestyle of those with regular work, as they may be more health aware. The Cancer Plan, however, suggests that relieving poverty may be more labour intensive and less rewarding than encouraging positive risk-reducing behaviour in all members of the population. Eating well can reduce the risk of developing many cancers, particularly of the stomach and bowel. The Cancer Plan outlines the ‘Five-a-Day’ programme which was rolled out in 2002 and encouraged people to eat at least five portions of fruit and vegetables per day. Obese people are also at higher risk of cancers, in particular endometrial cancer. A good diet and regular exercise not only reduce obesity but are also independent risk-reducing factors. Alcohol misuse is thought to be a major risk factor in around 3% of all cancers, with the highest risk for cancers of the mouth and throat. As part of the Cancer Plan, the Department of Health promotes physical activity and general health programmes, as well as alcohol and smoking programmes, particularly in deprived areas. Focusing on these healthy lifestyle points can potentially reduce an individual lifetime risk of all cancers. However, our knowledge of the biology of four cancers in particular has led to the development of specific life-saving interventions. Outlined in this chapter are details regarding ongoing prevention strategies for carcinomas of the lung, the breast, the bowel, and the cervix.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!